NCT01877109

Brief Summary

The purpose of this study is to establish a model which can predict the treatment outcome and the risk of treatment-related morbidity in patients with lymphoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,358

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 3, 2013

Completed
10 days until next milestone

First Posted

Study publicly available on registry

June 13, 2013

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2017

Completed
Last Updated

October 27, 2017

Status Verified

October 1, 2017

Enrollment Period

5.1 years

First QC Date

June 3, 2013

Last Update Submit

October 25, 2017

Conditions

Lymphoma

Keywords

LymphomaPrognosisBiomarkerQuality of life

Outcome Measures

Primary Outcomes (1)

  • All cause mortality

    Disease and non-disease-related mortality including treatment-related death

    5 years

Secondary Outcomes (4)

  • Treatment response

    1 year

  • Rate of occurrence of toxicity

    2 years from the start of the 1st therapy

  • Quality of life

    5 years

  • Biomarker development

    5 years

Study Arms (1)

Lymphoma

Lymphoma patients

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Newly visited lymphoma patients at the Samsung Medical Center

You may qualify if:

  • Patients who were diagnosed as lymphoma
  • Over 19 years old
  • Patients who agreed the enrollment of study
  • Informed consent for sampling

You may not qualify if:

  • Patients who do not want to join the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Samsung Medical Center

Seoul, South Korea

Location

Related Publications (2)

  • Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim WS, Kim SJ. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020 Feb 13;20(1):120. doi: 10.1186/s12885-020-6612-2.

    PMID: 32054467DERIVED

  • Kim SJ, Hong M, Do IG, Lee SH, Ryu KJ, Yoo HY, Hong JY, Ko YH, Kim WS. Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. Haematologica. 2015 Mar;100(3):e106-9. doi: 10.3324/haematol.2014.116087. Epub 2014 Dec 5. No abstract available.

    PMID: 25480498DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

1. Serum 2. Tissue specimen 3. DNA from peripheral blood mononuclear cells

MeSH Terms

Conditions

Lymphoma

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 3, 2013

First Posted

June 13, 2013

Study Start

February 1, 2012

Primary Completion

February 28, 2017

Study Completion

February 28, 2017

Last Updated

October 27, 2017

Record last verified: 2017-10

Locations

KR(1)